Market Intelligence, Clinical Progress, and High-Purity Reagents for Epileptic Encephalopathy & Neuropathic Pain Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCNT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-type & Mutant) | KCNT1 Membrane Protein / Extracellular Loop Fragments; Mutant Panel (Y796H, R428Q, R409Q, L243F, G288S). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View KCNT1 Products |
| Gene Delivery (Ion Channel) | KCNT1 Lentivirus Premade Particles. Full-length ORF for stable cell lines. Essential for patch-clamp and Thallium flux assays. Preserves native conformation. | View KCNT1 Products |
| Benchmark Ab | Anti-KCNT1 Reference Antibody (Validated Epitope). Recombinant positive control for binding assay development, surface expression detection, and immunocytochemistry. | View KCNT1 Products |
| Validator | KCNT1 siRNA Set. For knockdown verification, specificity controls in electrophysiology studies, and ASO mechanism benchmarking. | View KCNT1 Products |
| Related Target A | KCNT2 (Slack2). Homologous sodium-activated potassium channel for selectivity counter-screening. | View KCNT2 Products |
| Related Target B | KCNQ2. Epilepsy-associated potassium channel; synergistic pathway partner for combination strategies. | View KCNQ2 Products |
| Related Target C | SCN1A. Voltage-gated sodium channel, functionally coupled in neuronal excitability; relevant for Dravet syndrome combinatorial approaches. | View SCN1A Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformation & membrane topology (Ion channel assays) | Full-Length KCNT1 Lentivirus for stable cell line construction; HEK293 expressed. Cell-based assays preserve native glycosylation and gating. Lentivirus-based stable cell line generation ensures native quaternary structure in mammalian hosts. |
| Gain-of-Function Disease Modeling | Specific epilepsy-linked mutant ORFs strictly verified by sequencing for accurate phenotype replication. Mutant Protein Panel available for SPR/ITC binding studies. |
| Cross-species cyno/mouse evaluation | Human / Mouse / Cynomolgus KCNT1 ORF clones sequence-verified for ortholog comparison. |
| Subfamily off-target counter-screening (KCNT2 selectivity) / Off-Target Cardiac/CNS Toxicity | KCNT2 homolog products available; strict sequence discrimination by mass spec verified inserts. Comprehensive homolog panels (KCNT2, KCNQ2) for stringent selectivity profiling. |
| Lack of knockdown controls / False Positives in Screening | Validated siRNA included for specificity checks and ASO mechanism benchmarking. |
Live KCNT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNT1 therapeutics is intensifying, with research focus shifting from traditional anti-seizure medications to targeted precision therapeutics, specifically small molecule inhibitors and antisense oligonucleotides (ASOs). KCNT1 (Slack channel) gain-of-function mutations are the primary drivers of Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) and Malignant Migrating Partial Seizures of Infancy (MMPSI). As first-generation broad-spectrum therapies demonstrate limited efficacy due to lack of KCNT1 specificity, the next wave of R&D is heavily targeting mutant-specific channel blockers and RNA-targeted knockdown strategies designed to reduce hyperactive potassium efflux. Key players include Praxis Precision Medicines (small molecule inhibitors), Stoke Therapeutics and Ionis Pharmaceuticals (ASO/siRNA), and academic consortia exploring allosteric modulators. The scarcity of brain-penetrant, subtype-selective modulators positions KCNT1 as a high-value target for neurology-focused discovery programs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Channel Blocker / Inhibitor | Praxis Precision Medicines, Q-State Biosciences, University Labs | EIMFS, ADSHE, Rare Epilepsies, Refractory Epilepsy, Neuropathic Pain | High-Throughput Flux Assays (Need pure Lentivirus for HEK293 stable cells); Patch-Clamp Ready Cell Lines; Mutant vs WT Protein Selectivity Panels. |
| ASO / RNAi | Stoke Therapeutics, Ionis Pharmaceuticals, Biogen | KCNT1-Encephalopathy, MMPSI | Knockdown Validation (Need Sequence Verified Wild-type & Mutant Targets); qPCR Validation Standards. |
| Gene Therapy (AAV) | Novartis, Roche (Gene Therapy Units), Academic Biotechs | Pediatric Epileptic Encephalopathy, Developmental Epileptic Encephalopathy | Phenotypic Rescue Assays (Need accurate disease mutant templates); Cross-Species Epitope Validation (Human/Cyno/Mouse KCNT1). |
| Biologic Modulator | Early-stage ion channel innovators | Chronic Pain | Cell Surface Binding (Need lentivirus-expressed KCNT1 for FACS/SPR with native loops). |